Stockwinners Market Radar for June 06, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

Settings & Search

AMZN...		Hot Stocks 20:04 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The United States, Britain and other large, rich nations reached a landmark deal on Saturday to squeeze more money out of multinational companies such as Amazon (AMZN) and Google (GOOG) and reduce their incentive to shift profits to low-tax offshore havens, Reuters' David Milliken and Kate Holton reported. Hundreds of billions of dollars could flow into the coffers of governments left cash-strapped by the COVID-19 pandemic after the Group of Seven advanced economies agreed to back a minimum global corporate tax rate of at least 15%. Facebook (FB) said it expected it would have to pay more tax, in more countries, as a result of the deal, the authors noted. 2. Elon Musk said via Twitter that Tesla (TSLA) won't make Model S version Plaid +. "Model S goes to Plaid speed this week... Plaid+ is canceled. No need, as Plaid is just so good," he tweeted. 3. Zoom Video (ZM) has just completed what's arguably the best ever four-quarter earnings stretch for any large public company, Eric Savitz wrote in this week's edition of Barron's. But barring some nightmarish, unexpected change in the path of the pandemic, Zoom's days of incredible growth are over, the author contended, adding that for Zoom, the challenge now is how to leverage-and keep-the company's vastly expanded user base. 4. New Line and AT&T (T) subsidiary Warner Bros.' "The Conjuring: The Devil Made Me Do It" won this weekend's box office with a better-than-expected $24M domestic debut. The movie was also available at no extra charge to HBO Max costumers. Overseas, the horror film - the third Conjuring movie and the seventh film in the franchise - grossed $26.8M from 45 markets for a global total of $57.2M. 5. Pinnacle Financial (PNFP), Allegiance Bancshares (ABTX), PNC Financial (PNC), SVB Financial (SIVB), PTC (PTC), and Brinker International (EAT) saw positive mentions in this week's edition of Barron's.
TSLA		Hot Stocks 19:57 EDT Musk says Tesla not making Model S version 'Plaid+' - Tesla's Elon Musk said via Twitter that, "Model S goes to Plaid speed this week... Plaid+ is canceled. No need, as Plaid is just so good." Reference Link
SCHL		Hot Stocks 15:49 EDT Scholastic CEO M. Richard Robinson, Jr. dies unexpectedly - Scholastic announced that M. Richard Robinson, Jr. the company's Chairman and CEO passed away unexpectedly. Robinson, 84 years old, had been in excellent health and had been overseeing Scholastic's long-term strategic direction and day-to-day operations for the better part of five decades, the company said. James Barge, Scholastic's lead independent director, will work with Iole Lucchese, Executive Vice President, Chief Strategy Officer; Andrew Hedden, Executive Vice President, General Counsel and Secretary; and Kenneth Cleary, Chief Financial Officer to ensure that all day-to-day operations continue without interruption. The company's Class A shareholders and the company's board of directors will be meeting independently to determine the best course for the company's direction, including the appointment of an interim operating head.
IOVA		Hot Stocks 15:45 EDT Iovance Biotherapeutics announces 33-month follow up data for lifileucel - Iovance Biotherapeutics announced updated clinical data for lifileucel from Cohort 2 in the C-144-01 clinical study in patients with advanced melanoma. The data were presented in an oral presentation at the ASCO 2021 Annual Meeting. The long-term follow-up data for Cohort 2 in the C-144-01 clinical study continue to demonstrate durability and depth of lifileucel TIL therapy response. Median DOR was not reached at 33.1 months of median study follow up and Overall Response Rate, or ORR, remained at 36.4%. Responses deepened over time and one patient converted from partial to complete response at 24 months post lifileucel infusion. A multivariable model showed that for every six-month decrease in cumulative duration of prior anti-PD-1 therapy, DOR to lifileucel will be nearly doubled. These results suggest that early intervention with lifileucel at the time of initial progression on anti-PD-1 therapy may maximize benefit, the company said. All patients in Cohort 2 had high baseline disease burden and were heavily pretreated, including anti-PD1 and BRAF/MEK inhibitors if BRAFV600 mutation positive. The adverse event profile was consistent with the underlying advanced disease, lymphodepletion and IL-2 regimens, with no new safety risks identified for lifileucel during long-term follow-up.
NVS		Hot Stocks 06:27 EDT Novartis announces iptacopan met primary endpoint in IgAN Phase 2 study - Novartis announced Phase 2 primary endpoint data showing investigational iptacopan - a first-in-class, oral, targeted factor B inhibitor - reduced protein in the urine, an increasingly recognized surrogate marker correlating with progression to kidney failure, and showed promise in stabilizing kidney function in patients with IgA nephropathy, or IgAN. The data were presented at the 58th ERA-EDTA Congress held virtually from June 5-8. In the Phase 2 study, patients with IgAN were randomized to placebo or different doses of iptacopan. The primary endpoint was met with a statistically significant dose response effect on reduction in proteinuria. At the highest dose of 200mg twice daily a 23% reduction in proteinuria was predicted, compared with placebo, at 90 days. "These new data in IgAN add to the growing body of evidence around the potential of iptacopan to target a key driver in these rare renal diseases. Conscious of the significant patient need for disease-modifying treatment options, we are rapidly advancing clinical development of iptacopan with the Phase III IgAN trial APPLAUSE already underway," said John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis.